Torrent Pharmaceuticals Limited has scheduled a board meeting for February 13, 2026, to review its quarterly financial performance and consider dividend distribution to shareholders. The pharmaceutical company made this announcement through a regulatory filing dated February 2, 2026, addressed to both BSE Limited and National Stock Exchange of India Limited.

Board Meeting Agenda

The upcoming board meeting will focus on two primary areas of business. The directors will consider and approve the company's financial results for the quarter and nine months ended December 31, 2025. Additionally, the board will deliberate on the payment of interim dividend for the financial year 2025-26.

Financial Results Structure

The board will review financial results in two distinct formats to provide comprehensive transparency to stakeholders. The standalone financial results will be presented in audited format, ensuring thorough verification and compliance with accounting standards. Meanwhile, the consolidated financial results will be unaudited but subject to limited review procedures.

Regulatory Compliance

The announcement was made in strict adherence to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results and dividend decisions are scheduled for consideration. The filing was signed by Chintan M. Trivedi, Company Secretary, demonstrating proper corporate governance protocols.

Market Communication

Torrent Pharmaceuticals communicated this development to both major Indian stock exchanges simultaneously. The company addressed the notification to BSE Limited's Corporate Relationship Department and National Stock Exchange of India Limited's Listing Department, ensuring comprehensive market disclosure and maintaining transparency with all stakeholders.

Torrent Pharmaceuticals Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection at its Dahej manufacturing facility with zero observations, marking a significant regulatory milestone for the pharmaceutical company.

Inspection Details

The USFDA conducted a comprehensive inspection of the Dahej manufacturing facility over a five-day period. The inspection parameters and outcomes are detailed below:

Regulatory Compliance Achievement

The completion of the USFDA inspection with zero observations represents a clean regulatory outcome for Torrent Pharmaceuticals. Zero observations indicate that the inspection team found no deficiencies or areas of concern during their comprehensive review of the facility's manufacturing processes, quality systems, and compliance protocols.

This outcome demonstrates the company's adherence to stringent international manufacturing standards and regulatory requirements set by the USFDA for pharmaceutical facilities.

Stock Exchange Notification

Torrent Pharmaceuticals has formally notified both major Indian stock exchanges about this development in compliance with regulatory disclosure requirements:

• BSE Limited: Notification sent under Scrip Code 500420
• National Stock Exchange: Notification sent under Symbol TORNTPHARM
• Regulatory Framework: Disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The notification was signed by Chintan M. Trivedi, Company Secretary, and submitted on January 23, 2026.

Manufacturing Facility Significance

The Dahej facility represents an important manufacturing asset for Torrent Pharmaceuticals in its pharmaceutical operations. The successful completion of this USFDA inspection without any observations strengthens the facility's regulatory standing and validates the company's manufacturing capabilities for potential US market operations.

This regulatory clearance enhances the company's compliance track record and supports its pharmaceutical manufacturing operations under international quality standards.